Michael came in with a printout from his doctor. TSH: 2.8 mIU/L. “Normal,” his doctor had written at the top in red pen. Michael was gaining weight despite a calorie-deficit diet, losing his hair, exhausted by 2 PM every day, struggling with depression that wasn’t responding to an SSRI, and cold in rooms where his colleagues were comfortable. Three years, this had been going on.
His doctor, looking at that TSH value, concluded his thyroid was fine. What his doctor hadn’t looked at — because it wasn’t on the standard panel — was Free T3 of 2.1 (low-normal), Free T4 of 0.8 (below reference range), and Anti-TPO antibodies of 847 IU/mL (dramatically elevated). Hashimoto’s thyroiditis, actively destroying his thyroid gland.
Not an unusual story. It’s one of the more common clinical failures in primary care, actually: using a single marker (TSH) to evaluate an extraordinarily complex hormonal system with multiple conversion steps, regulatory feedback loops, and tissue-level effects a single number simply cannot capture. The full thyroid panel — ordered and interpreted comprehensively — tells a far richer, far more clinically actionable story than TSH alone ever will.
Understanding what each marker means, how they relate to each other, and what the patterns indicate clinically matters for anyone dealing with thyroid-related symptoms, or managing a condition already diagnosed.
The Thyroid Hormone System — Architecture First
Thyroid hormone physiology runs through five major steps, each one a possible site of dysfunction, each one reflected in a different lab marker. Understand the architecture, and the lab values stop looking arbitrary.
Step one: hypothalamic signaling. The hypothalamus produces thyrotropin-releasing hormone (TRH) in response to low thyroid hormone, cold, stress, and other inputs. TRH travels to the anterior pituitary. Step two: pituitary stimulation. TRH prompts the pituitary to produce thyroid-stimulating hormone (TSH), which travels to the thyroid gland through the bloodstream. TSH is what most thyroid testing measures — a pituitary signal, worth remembering, not a thyroid hormone itself. Step three: thyroid hormone production.
TSH stimulates thyroid follicular cells to take up iodide, incorporate it into thyroglobulin, and produce thyroxine (T4, four iodine atoms) plus a smaller amount of triiodothyronine (T3, three iodine atoms). The thyroid produces roughly 80 percent T4, 20 percent T3.
Step four: hormone transport. T4 and T3 release into the bloodstream mostly bound to carrier proteins (thyroid binding globulin, transthyretin, albumin). Only the unbound “free” fraction is biologically active — which is exactly why Free T4 (FT4) and Free T3 (FT3) matter clinically, not total T4 and total T3.
Total hormone measurements reflect both bound and free fractions and get heavily swayed by carrier protein levels, which shift with estrogen, pregnancy, liver disease, and other factors that have nothing to do with actual thyroid function. Step five: peripheral conversion. T4 is the storage form — relatively weak biological activity on its own.
It has to be converted to the active T3 form in peripheral tissues (liver, gut, kidneys, muscle, brain) by deiodinase enzymes, particularly type 1 and type 2 (DIO1 and DIO2). This conversion step is exactly where many cases of “normal thyroid tests but symptomatic hypothyroidism” are actually hiding.
Reverse T3 (rT3) is another conversion product: T4 can turn into rT3 instead of active T3, via type 3 deiodinase (DIO3). rT3 is biologically inactive and — more importantly — it competes with T3 for receptor binding, meaning elevated rT3 can effectively block T3 action at the cellular level even when FT3 looks adequate in the blood. This happens preferentially during caloric restriction, severe illness, high cortisol states, and selenium deficiency.
TSH — What It Actually Measures
TSH is the most sensitive single marker for primary thyroid dysfunction — dysfunction originating in the thyroid gland itself. In primary hypothyroidism (insufficient thyroid hormone production), TSH rises as the pituitary tries to drive more production. In primary hyperthyroidism (excess production), TSH falls as the pituitary dials back its signal. Useful screening test, for the most common forms of thyroid dysfunction.
The reference range problem matters here, and it’s worth understanding. TSH reference range varies by lab but typically runs 0.4 to 4.0, or 0.5 to 4.5 mIU/L, in most conventional labs.
That range came from population studies that included undiagnosed individuals with subclinical thyroid disease — in other words, the “normal” reference range got contaminated by symptomatic patients nobody had diagnosed yet, artificially widening what counted as normal. The American College of Clinical Endocrinology recommended narrowing the upper limit to 3.0 mIU/L back in 2002, citing evidence that TSH above 2.5 tracks with increased risk of progression to overt hypothyroidism, and with symptoms in sensitive individuals.
Plenty of functional medicine practitioners use an optimal TSH range of 1.0 to 2.0 mIU/L, based on population studies showing minimal thyroid disease at those values.
TSH has real limitations, though. It doesn’t reflect step four (free hormone availability) or step five (peripheral conversion to active T3). A patient can have a “normal” TSH with impaired T4-to-T3 conversion and be functionally hypothyroid at the cellular level regardless. TSH can also be artificially suppressed or elevated by non-thyroid factors: high-dose biotin supplementation (common in hair loss treatments) falsely lowers TSH in biotin-based assays; glucocorticoids suppress it; dopamine agents lower it; acute illness suppresses it too.
Worth keeping all of that in mind when interpreting a TSH result.
Secondary hypothyroidism — where the problem sits in the pituitary or hypothalamus rather than the thyroid gland itself — produces low or normal TSH alongside low free thyroid hormones. Here TSH is a genuinely misleading marker: it looks “normal” despite the patient being hypothyroid. Less common than primary hypothyroidism, but it needs different diagnosis and management. Testing FT4 and FT3 alongside TSH is the guardrail against missing it.
Free T4 and Free T3 — the Active Hormone Story
Free T4 reflects the thyroid’s output of its primary secretory product — the T4 prohormone. Low FT4 with elevated TSH confirms primary hypothyroidism: the thyroid isn’t producing enough T4, and the pituitary is pushing harder to compensate. Normal FT4 with elevated TSH indicates mild or subclinical hypothyroidism — the pituitary is holding T4 in the normal range, but at the cost of elevated TSH signaling. The thyroid is laboring, in other words, even if the output number still looks fine.
Free T3 is the more biologically important marker in many clinical contexts, because T3 is the hormone that actually binds nuclear receptors and regulates gene expression in target tissues. T3 has four to five times the receptor affinity of T4. Symptoms of hypothyroidism — fatigue, brain fog, weight gain, cold intolerance, constipation, hair loss, depression — correlate better with FT3 than with FT4 or TSH across several studies.
Particularly relevant for patients on standard levothyroxine (T4-only) therapy who stay symptomatic despite normalized TSH and FT4 — if peripheral T4-to-T3 conversion is impaired, FT3 can stay low even while everything upstream looks normalized.
A landmark 2019 study in Thyroid by Idrees and colleagues found roughly 20 percent of patients treated with levothyroxine for hypothyroidism keep experiencing symptoms consistent with residual hypothyroidism, despite normalized TSH. This group runs significantly lower FT3 levels than non-hypothyroid controls, and lower FT3-to-FT4 ratios — consistent with impaired T4-to-T3 conversion.
This is the clinical basis for adding T3 (liothyronine/synthetic T3, or desiccated thyroid extract, which carries both T4 and T3) to treatment in symptomatic patients whose FT3 stays low despite TSH normalization.
The FT3/FT4 ratio is increasingly used as a marker of T4-to-T3 conversion efficiency. A low ratio (FT3 low relative to FT4) points to impaired deiodinase activity. Causes: selenium deficiency (selenium is required for DIO1 and DIO2), zinc deficiency, high cortisol (stress, HPA dysfunction), caloric restriction, elevated inflammatory cytokines (IL-6, TNF-alpha inhibit deiodinase), insulin resistance, and genetic DIO2 variants affecting T4-to-T3 conversion efficiency in certain tissues, the brain included.
Reverse T3 — the Conversion Blockade Marker
This is “euthyroid sick syndrome,” or “low T3 syndrome” — an adaptive mechanism conserving energy during acute illness by lowering metabolic rate. Makes sense, in the short term.
The controversy around rT3 testing is whether this adaptive response turns maladaptively persistent in chronic illness, feeding ongoing hypothyroid symptoms despite technically “normal” thyroid function. The clinical observation: many chronically ill patients — ME/CFS, adrenal dysfunction, chronic infections, prolonged caloric restriction — carry elevated rT3 that doesn’t resolve once the acute trigger resolves, potentially locking in a functional hypothyroid state.
The rT3-to-FT3 ratio, rather than absolute rT3, is used by many functional medicine practitioners as a guide to T3 receptor availability: high rT3 competing with FT3 for receptor binding suggests functional hypothyroidism even when individual values look fine on paper. A common clinical threshold is an FT3/rT3 ratio below 20 (FT3 in pg/mL, rT3 in ng/dL) as a flag for possible T3 resistance from receptor competition.
That threshold isn’t derived from large validation studies, worth noting, and should be read as one piece of the overall clinical picture rather than a definitive diagnostic line.
Thyroid Antibodies — the Autoimmune Dimension
Anti-thyroid peroxidase antibodies (Anti-TPO) and anti-thyroglobulin antibodies (Anti-TG) are the primary markers of autoimmune thyroid disease — the most common cause of hypothyroidism in iodine-sufficient regions worldwide.
Hashimoto’s thyroiditis shows elevated Anti-TPO antibodies (present in roughly 90 to 95 percent of Hashimoto’s patients) and elevated Anti-TG antibodies (roughly 80 percent). The antibodies cause damage by directing immune attack against thyroid peroxidase (the enzyme handling iodine incorporation and thyroid hormone synthesis) and thyroglobulin (the protein matrix thyroid hormone gets synthesized on). The result is progressive inflammatory destruction of thyroid tissue over years to decades, eventually producing overt hypothyroidism.
The critical clinical point: Anti-TPO antibodies can be elevated, and Hashimoto’s can be actively progressing, while TSH still sits within the normal range. Michael’s case shows exactly this — his TSH of 2.8 fell within the standard reference range, but his Anti-TPO of 847 IU/mL signaled massive ongoing autoimmune attack on his thyroid. Treating TSH as the sole marker, and calling his thyroid “fine,” missed the active autoimmune destruction that would eventually drive overt hypothyroidism.
The significance of positive antibodies in euthyroid (normal TSH) individuals is well studied. The Whickham Survey, a large UK population study with twenty-year follow-up, found women with positive TPO antibodies and normal TSH carried a 3.8 percent annual risk of developing overt hypothyroidism — twenty times higher than antibody-negative women. Positive antibodies warrant closer monitoring of thyroid function and, in functional medicine practice, consideration of interventions targeting the underlying autoimmune process itself.
Graves’ disease — the primary cause of hyperthyroidism — is tied to TSH receptor antibodies (TRAb), specifically thyroid-stimulating immunoglobulins (TSI) that bind and activate TSH receptors, driving excess thyroid hormone production. Anti-TPO antibodies are also elevated in most Graves’ patients. TSI measurement confirms the Graves’ diagnosis, differentiates it from other causes of hyperthyroidism, predicts relapse after antithyroid drug withdrawal, and assesses neonatal Graves’ risk in pregnant women with the condition.
Anti-TG antibodies carry lower specificity for Hashimoto’s than Anti-TPO (they can be elevated in differentiated thyroid cancer and other conditions), but add information when Anti-TPO is negative in a patient with strong clinical suspicion of autoimmune thyroid disease — roughly 10 percent of Hashimoto’s patients are Anti-TPO negative but Anti-TG positive.
For thyroid cancer monitoring, thyroglobulin (Tg) itself is used as a tumor marker after thyroidectomy, and Anti-TG antibodies get measured alongside it because they interfere with the Tg assay when present.
Thyroid Ultrasound — the Structural Complement to Blood Testing
Blood tests measure the functional and immunological aspects of thyroid status. Thyroid ultrasound provides structural information — nodule detection, gland size, echogenicity, vascular patterns — that complements it, and that lab testing simply can’t replace. A comprehensive thyroid evaluation, in the right clinical context, includes both.
Thyroid ultrasound can detect nodules as small as 2 to 3 mm — far below what physical examination can find. American Thyroid Association guidelines recommend ultrasound for any palpable thyroid abnormality, incidentally detected nodules, patients with radiation history, and first-degree relatives of thyroid cancer patients. The ACR TIRADS classification system (Thyroid Imaging Reporting and Data System) stratifies nodules by ultrasound characteristics into risk categories that guide biopsy decisions.
Hashimoto’s produces characteristic ultrasound findings: heterogeneous echotexture, reduced echogenicity (a dark gland), coarse texture, and in some cases pseudo-nodularity. These findings can confirm a Hashimoto’s diagnosis in cases with positive antibodies, and occasionally detect autoimmune thyroid disease even in patients with negative antibodies — roughly 5 percent of Hashimoto’s patients are seronegative but show the characteristic sonographic changes anyway.
Addressing Hashimoto’s — Beyond Replacing the Hormone
Several interventions have evidence behind them for reducing TPO antibody titers and thyroid inflammation in Hashimoto’s. A gluten-free diet in patients with positive celiac serology or anti-gliadin antibodies has shown reductions in TPO antibody titers in both randomized and observational studies — molecular mimicry between gliadin epitopes and thyroid tissue antigens offers a plausible mechanism for the connection.
A 2012 Italian study found significant TPO titer reduction at twelve months on a strict gluten-free diet in Hashimoto’s patients with positive anti-gliadin antibodies.
Selenium supplementation has the strongest evidence of all for TPO antibody reduction. Selenium is required for selenoproteins including glutathione peroxidase (which reduces inflammatory hydrogen peroxide in the thyroid) and the deiodinases themselves. Multiple randomized controlled trials have shown selenium supplementation at 200 µg daily (as selenomethionine or selenium-enriched yeast) significantly reduces TPO antibody titers — a 2002 German trial found a 50 percent reduction in TPO titers over six months in selenium-deficient Hashimoto’s patients.
Selenium deficiency is common in plenty of regions, particularly where soil selenium runs low to begin with.
Low-dose naltrexone (LDN) has been reported in case series to reduce thyroid antibody titers and improve symptoms in Hashimoto’s patients, presumably through immune-modulating effects on regulatory T-cells and natural killer cells. Controlled trials specifically in Hashimoto’s remain limited, but the immune mechanism tracks, given the autoimmune nature of the condition.
Vitamin D optimization is another well-supported intervention — multiple studies document lower vitamin D levels in Hashimoto’s patients than in controls, and vitamin D carries documented immune-regulatory effects, including suppression of Th17 and promotion of regulatory T-cells, both relevant to autoimmune control.
The Optimal Ranges Debate
One of the more practically contentious areas in thyroid medicine is “optimal” versus “normal” reference ranges. Conventional reference ranges are statistical — the middle 95 percent of a reference population that may well include subclinically ill individuals. Functional medicine practitioners argue that “optimal” ranges — those tied to minimal symptoms and disease risk in population studies — are narrower and more clinically meaningful than the broad statistical normal range.
For TSH, the optimal range debate centers on the upper limit. As covered above, there’s evidence TSH above 2.5 tracks with symptom burden and progression risk in some populations. Clinical reality: some people feel fine at a TSH of 3.5, others feel lousy at 2.5. Individual variation is real here, and it’s relevant.
A TSH sitting near the top of the reference range in a symptomatic patient warrants measuring FT3, FT4, and antibodies — not dismissing the symptoms as unrelated to the thyroid on the strength of one “normal” TSH alone.
For FT3, the clinical evidence strongly favors treating toward the upper half of the reference range rather than just landing “within normal limits.” A 2013 study by Appelhof and colleagues found hypothyroid patients had significantly better cognitive performance and quality of life on combination T4/T3 therapy versus T4 alone, specifically correlating with higher FT3 levels.
The optimal FT3 range in most panels runs roughly 3.0 to 4.5 pg/mL (3.1 to 6.8 in many labs), though individual optimal levels vary, and symptom assessment alongside the lab values tells more than chasing one specific number ever will.
Thyroid Hormone System Q&A
My TSH is normal but I have all the symptoms of hypothyroidism. What should I do?
Request a comprehensive thyroid panel: TSH, Free T4, Free T3, Reverse T3, Anti-TPO, Anti-TG. Give the physician specific reasons for each marker — walk through the conversion and antibody stories covered above. Physician won’t order the full panel? A functional medicine physician or an endocrinologist with an interest in thyroid optimization may be more receptive.
If the expanded panel turns up Hashimoto’s (positive antibodies), low FT3, or elevated rT3, there are objective findings to anchor a treatment discussion. If every marker truly sits within optimal ranges, consider other causes of hypothyroid-like symptoms: iron deficiency anemia, adrenal dysfunction, a sleep disorder, depression, and nutrient deficiencies (particularly B12, D, and magnesium) can all produce a strikingly similar symptom cluster.
Is Hashimoto’s reversible?
Thyroid tissue already destroyed by Hashimoto’s doesn’t regenerate. But the autoimmune process itself can be slowed, halted, or in some cases significantly reduced through the right interventions. Measurable reduction in TPO antibody titers — the primary marker of active autoimmune attack — is achievable for many patients through selenium supplementation, vitamin D optimization, gluten elimination (when indicated), stress management, and gut health restoration.
Whether antibody reduction translates into preserved remaining thyroid function depends on the disease stage when intervention begins, plus individual factors. Early intervention in patients with positive antibodies but still-normal thyroid function offers the best shot at preventing or delaying progression to overt hypothyroidism.
What is the difference between hypothyroidism and Hashimoto’s?
Hashimoto’s thyroiditis is an autoimmune condition where the immune system attacks the thyroid gland. Hypothyroidism is the state of insufficient thyroid hormone production. Hashimoto’s is the most common cause of hypothyroidism in iodine-sufficient countries, but the two aren’t synonymous. A patient can have Hashimoto’s (positive antibodies, active immune attack) with normal thyroid function, if the remaining thyroid tissue is still compensating adequately.
A patient can have hypothyroidism without Hashimoto’s, too — iodine deficiency, surgical thyroid removal, radioactive iodine treatment, other causes. The distinction matters because Hashimoto’s carries specific management considerations (autoimmune modulation) beyond simple hormone replacement.
How does iodine affect thyroid function and should I supplement it?
Iodine is required for thyroid hormone synthesis — incorporated into the tyrosine residues of thyroglobulin to produce T4 and T3. Iodine deficiency causes hypothyroidism, and it’s the most common preventable cause of intellectual disability worldwide.
That said, iodine supplementation in patients with Hashimoto’s is controversial, and potentially harmful: excess iodine can raise TPO antibody titers and accelerate thyroid autoimmunity in susceptible individuals, likely by increasing thyroglobulin’s immunogenicity and by generating hydrogen peroxide during thyroid hormone synthesis, driving oxidative stress and immune activation. Selenium deficiency amplifies this — selenium is required for the glutathione peroxidase that neutralizes that hydrogen peroxide.
The appropriate approach for Hashimoto’s patients is ensuring iodine adequacy, not deficiency, from dietary sources, while avoiding excess iodine supplementation. A 24-hour urine iodine test can assess status before any supplementation decision gets made.
Should I be taking desiccated thyroid extract (like Armour Thyroid) instead of levothyroxine?
Desiccated thyroid extract (DTE), derived from porcine thyroid glands, contains both T4 and T3 in roughly the same 4:1 ratio as human thyroid secretion. Levothyroxine provides only T4, relying on peripheral conversion for T3. For patients who convert T4 to T3 normally, levothyroxine is physiologically adequate — equivalent to DTE, for practical purposes.
For patients with impaired T4-to-T3 conversion — the 20 percent of treated hypothyroid patients who stay symptomatic on levothyroxine — DTE or combination T4/T3 therapy may produce better outcomes. Several randomized crossover studies have found a significant proportion of patients prefer DTE to levothyroxine when both get tried, with better cognitive and mood outcomes reported.
DTE isn’t right for everyone (the T3 content can cause palpitations and anxiety in some, and dosing is less flexible than levothyroxine), but it’s a legitimate therapeutic option for symptomatic patients whose FT3 stays low on levothyroxine monotherapy.
Thyroid in the Context of Other Systems
The thyroid-adrenal relationship matters most here. Cortisol and thyroid hormones have opposing effects on many metabolic processes, and they regulate each other’s activity in turn. High cortisol — chronic stress, HPA dysfunction, steroid medications — suppresses TSH secretion, inhibits T4-to-T3 conversion (by upregulating rT3 production), and reduces thyroid hormone receptor sensitivity. The result is functional hypothyroidism driven by cortisol excess, not intrinsic thyroid failure.
In that scenario, treating only the thyroid without touching the adrenal dysfunction is inadequate, and can even backfire — adding T3 to an already high-cortisol system can trigger palpitations, anxiety, cardiovascular stress.
Adrenal insufficiency — low cortisol, whether from primary adrenal failure or secondary HPA axis dysregulation — also complicates thyroid interpretation. Cortisol is required for appropriate thyroid hormone receptor expression; low cortisol can reduce thyroid hormone response at the cellular level, producing hypothyroid symptoms despite adequate circulating thyroid hormone.
The classic presentation is someone with both low cortisol and low thyroid function who gets worse once thyroid hormone replacement starts, because the increased metabolic rate isn’t supported by inadequate cortisol underneath it — and it requires treating both systems at once, not sequentially.
Estrogen profoundly affects thyroid binding globulin (TBG) production — estrogen raises TBG, binding more T4 and T3 in the carrier-bound, inactive form. Which is why total T4 and T3 run elevated in pregnant women and oral contraceptive users, while the free (active) fractions may stay flat or drop. Women moving through perimenopause often develop or worsen thyroid symptoms as estrogen fluctuates, shifting TBG and therefore free hormone availability underneath them.
The interaction between thyroid and sex hormones runs both directions, too: hypothyroidism raises prolactin (which can suppress ovarian function), alters sex hormone binding globulin, and impairs progesterone production — a whole hormonal cascade from a single thyroid dysfunction.
Gut health directly affects thyroid function through several pathways. Roughly 20 percent of T4-to-T3 conversion happens in the gut, catalyzed by gut bacterial enzymes. Gut dysbiosis impairs this conversion, reducing FT3 availability. Intestinal permeability from dysbiosis lets LPS into systemic circulation, driving inflammatory cytokine production that inhibits deiodinase activity and pushes conversion toward rT3. Gut bacteria deconjugate thyroid hormones entering the gut via bile — disrupted gut flora impairs this recycling, reducing thyroid hormone reabsorption.
A comprehensive approach to hypothyroidism, then, includes gut health as a core therapeutic target. Not a peripheral concern tacked on at the end.
Nutrient status beyond selenium and iodine matters too. Iron is required for thyroid peroxidase activity — iron-deficiency anemia impairs thyroid hormone synthesis and blunts the effectiveness of iodine. Zinc is required for both T4-to-T3 conversion (a cofactor for deiodinase) and thyroid hormone receptor binding. Vitamin A is required for thyroid receptor expression. Magnesium affects TSH secretion. Tyrosine is the amino acid backbone of thyroid hormones — T4 is literally two iodinated tyrosines joined together.
A comprehensive nutritional assessment is therefore relevant to thyroid optimization — checking and correcting iron, zinc, vitamin D, selenium, and magnesium before or alongside thyroid hormone replacement may reduce the required medication dose, or simply improve the treatment response.
Reading a Thyroid Panel — a Practical Walkthrough
Given how complex thyroid physiology and lab testing get, a practical framework for reading a panel helps turn understanding into clinical action. The following sequence applies the mechanistic concepts to actual lab values.
Start with TSH as the initial orientation. Suppressed (below 0.4)? Suggests hyperthyroidism or exogenous thyroid hormone excess (over-medication), absent pituitary disease. Elevated (above 2.5 in a functional medicine context, above 4.5 conventionally)? Suggests the pituitary is working harder to maintain thyroid hormone levels — primary thyroid dysfunction. Lower part of the normal range (0.5 to 1.5)?
Typically associated with good thyroid function, though it still warrants FT3 evaluation in a symptomatic patient.
Look at FT4 next. Low despite elevated TSH? Confirms the pituitary-thyroid communication is working (TSH is being produced) but the thyroid isn’t responding adequately — consistent with Hashimoto’s or other primary hypothyroid causes. Normal FT4 despite elevated TSH? The thyroid is compensating to hold T4 steady, but it’s struggling — worth monitoring, worth checking FT3. FT4 elevated with suppressed TSH? Consistent with hyperthyroidism — evaluate for Graves’ (TSI), toxic nodule, or thyroiditis.
Look at FT3, particularly against FT4. Calculate the FT3/FT4 ratio (FT3 divided by FT4, both in pg/mL). A ratio below 0.3 suggests impaired conversion. FT3 low despite normal FT4 and TSH? That’s the pattern of impaired T4-to-T3 conversion — a conversion problem, not a production problem. FT3 in the lower half of the range in a symptomatic patient? Worth considering treatment optimization regardless of how normal TSH and FT4 look.
Look at the antibodies. Elevated Anti-TPO (above 35 IU/mL in most labs), with or without elevated Anti-TG, indicates Hashimoto’s. The magnitude matters clinically — Anti-TPO of 60 represents a very different inflammatory burden than Anti-TPO of 2,000, even though both technically read “positive.” Elevated TSI (thyroid stimulating immunoglobulin) indicates Graves’ disease. Monitoring antibodies over time — quarterly or semi-annually — tracks whether the autoimmune process is progressing, holding steady, or responding to intervention.
Finally, rT3 if the panel includes it. Upper half of normal, or elevated? Is the FT3/rT3 ratio (FT3 in pg/mL divided by rT3 in ng/dL) below 20? Suggests significant T4 diversion toward the inactive form, potentially driven by cortisol, inflammation, caloric restriction, or selenium deficiency. Addressing the underlying driver — not just piling on more T3 — is the right first move.
Michael, with his TSH of 2.8, FT3 of 2.1, FT4 of 0.8, and Anti-TPO of 847, had a clear picture once the full panel got interpreted properly: Hashimoto’s thyroiditis with early subclinical hypothyroidism (FT4 and FT3 falling despite TSH still sitting in range) and active autoimmune attack confirmed by the elevated antibodies.
His treatment: selenium 200 µg daily, vitamin D repletion to 65 ng/mL, a gluten elimination trial with anti-gliadin IgA confirmation on GI-MAP, and low-dose levothyroxine to bring FT4 and FT3 into the optimal range. At six months, his Anti-TPO had fallen to 312 IU/mL. His fatigue, hair loss, and cold intolerance had dramatically improved. His depression — never really a psychiatric illness to begin with — had resolved entirely.
The TSH that said “normal” had been telling the wrong story the whole time.
Special Populations — Pregnancy, Children, and the Elderly
Thyroid function changes dramatically across the lifespan and in specific physiological states. Pregnancy especially creates profound shifts in thyroid physiology that require different lab reference ranges and different management thresholds than in non-pregnant adults.
During pregnancy, hCG (human chorionic gonadotropin) from the placenta cross-reacts with TSH receptors, stimulating thyroid hormone production in the first trimester. This produces a physiological drop in TSH during the first trimester (sometimes below 0.5) that would look like hyperthyroidism in a non-pregnant person but is entirely normal in early pregnancy. At the same time, estrogen-driven TBG increase raises total T4 and T3 while the free fractions may hold steady.
Pregnancy-specific TSH reference ranges (lower in the first trimester) and trimester-specific FT4 ranges have to be used for pregnant women — the standard non-pregnant ranges simply don’t apply.
Untreated or undertreated hypothyroidism during pregnancy carries real risks: miscarriage, preterm birth, placental abruption, and impaired fetal neurodevelopment (T4 is critical for fetal brain development, especially in the first trimester before the fetal thyroid is even functional). The consensus recommendation is keeping TSH below 2.5 mIU/L throughout pregnancy, which often means raising the levothyroxine dose 25 to 30 percent once pregnancy is confirmed.
Women with Hashimoto’s — even with a normal pre-pregnancy TSH — should have thyroid function checked immediately once pregnancy is confirmed, and monitored every four to six weeks throughout.
In children and adolescents, subclinical hypothyroidism is common, and management runs more conservative than in adults — many kids with TSH of 4.5 to 10 mIU/L and normal FT4 get monitored without treatment, since a significant share normalize spontaneously on their own.
That said, positive Anti-TPO antibodies in a child or adolescent, indicating Hashimoto’s, warrants monitoring, consideration of selenium and vitamin D optimization, and attention to gluten sensitivity — pediatric Hashimoto’s has a notable association with celiac disease, and both should get screened for together.
In elderly patients, TSH reference ranges shift upward with age — a TSH of 5 to 7 mIU/L may be appropriate, even protective, in patients over 80, since suppressed TSH in elderly individuals ties to higher cardiovascular mortality and osteoporosis risk. Aggressive thyroid treatment aimed at “optimal” targets appropriate for younger adults can actually cause harm in this population.
The management goal in elderly patients is typically holding TSH within the age-adjusted reference range while watching for both hypo- and hyperthyroid symptoms — recognizing that atypical presentations (atrial fibrillation, cognitive decline, depression) show up more often than classic thyroid symptoms in this age group.
The Practical Framework: Applying Thyroid Hormone System Architecture In Real Life
References